Avanos Medical Reports Q4 & Full-Year 2025 Results, Exceeds Revenue & EPS Guidance, Issues 2026 Outlook
Summary
Avanos Medical announced Q4 and full-year 2025 results, surpassing its full-year revenue and adjusted EPS guidance, and provided a 2026 outlook for net sales and adjusted EPS.
Key Events
-
Exceeded 2025 Full-Year Guidance
The company exceeded its full-year revenue targets and achieved the top end of its adjusted earnings-per-share guidance for 2025, reporting $701.2 million in net sales and $0.94 adjusted diluted EPS.
-
Q4 2025 Performance
Fourth quarter net sales increased 0.7% to $180.9 million. Adjusted diluted EPS was $0.29, compared to $0.43 in the prior year, while adjusted operating income was $22.6 million.
-
2026 Financial Outlook Provided
Avanos Medical expects 2026 net sales to be between $700 million and $720 million, with adjusted diluted earnings per share projected to be between $0.90 and $1.10.
-
Strategic Progress and Debt Reduction
The company achieved 6% organic growth in strategic segments for the full year and reduced net debt to $10.7 million. Transformation initiatives are expected to deliver $15 to $20 million in incremental annualized savings by the end of 2026.
Analysis
Avanos Medical, Inc. reported its fourth quarter and full-year 2025 financial results, notably exceeding full-year revenue and achieving the top end of its full-year adjusted earnings-per-share guidance. This performance, following the 2025 estimates provided in January, demonstrates the company's ability to meet its internal targets. While adjusted operating profit and EBITDA for the full year 2025 were lower compared to 2024, the company made significant progress in reducing its net debt and advancing transformation initiatives expected to yield substantial annualized savings by the end of 2026. The 2026 outlook projects relatively stable net sales and adjusted diluted EPS, indicating a focus on consistent performance and operational efficiency rather than aggressive growth.
At the time of this filing, AVNS was trading at $15.23 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $707M. The 52-week trading range was $9.30 to $16.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.